Peptipedia
Weight LossFDA ApprovedFDA Approved

Tirzepatide

Also known as Mounjaro, Zepbound, LY3298176

A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.

FDA Approved - Type 2 diabetes, chronic weight management, obstructive sleep apnea
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

5-15 mg weekly (after titration)

Frequency

Once weekly

Duration

Long-term / chronic use

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 5-15 mg weekly (after titration) via Subcutaneous injection weekly, Once weekly. Dose range: 2.5-15 mg weekly. Duration: Long-term / chronic use.

Timing & Administration

Administer via Subcutaneous injection weekly. Frequency: Once weekly.

Mechanism of Action

Activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. Enhanced glucose-dependent insulin release while glucagon decreases and gastric emptying slows.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Type 2 diabetes, chronic weight management, obstructive sleep apnea.

Side Effects & Safety

Important Warnings

  • Boxed Warning: Contraindicated in patients with medullary thyroid carcinoma (MTC) or MEN 2
Nausea
diarrhea
vomiting
constipation
decreased appetite
abdominal pain
injection site reactions
hypoglycemia
pancreatitis
gallbladder problems
acute kidney injury

References

No references available.

Related Peptides

Browse all →
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile
RetatrutideWeight Loss

A triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.

View profile
LiraglutideWeight Loss

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing. 97% homology to native GLP-1.

View profile